TİGEN, M. K. Et Al. 2021. Bleeding risk with concomitant use of tirofiban and third-generation P2Y12 receptor antagonists in patients with acute myocardial infarction: A real-life data.. Anatolian journal of cardiology , vol.25, no.10 , 699-705.

TİGEN, M. K., Ozdil, M. H., Cincin, A., Gurel, E., SÜNBÜL, M., Sahin, A., ... Guctekin, T.(2021). Bleeding risk with concomitant use of tirofiban and third-generation P2Y12 receptor antagonists in patients with acute myocardial infarction: A real-life data.. Anatolian journal of cardiology , vol.25, no.10, 699-705.

TİGEN, MUSTAFA Et Al. "Bleeding risk with concomitant use of tirofiban and third-generation P2Y12 receptor antagonists in patients with acute myocardial infarction: A real-life data.," Anatolian journal of cardiology , vol.25, no.10, 699-705, 2021

TİGEN, MUSTAFA K. Et Al. "Bleeding risk with concomitant use of tirofiban and third-generation P2Y12 receptor antagonists in patients with acute myocardial infarction: A real-life data.." Anatolian journal of cardiology , vol.25, no.10, pp.699-705, 2021

TİGEN, M. K. Et Al. (2021) . "Bleeding risk with concomitant use of tirofiban and third-generation P2Y12 receptor antagonists in patients with acute myocardial infarction: A real-life data.." Anatolian journal of cardiology , vol.25, no.10, pp.699-705.

@article{article, author={MUSTAFA KÜRŞAT TİGEN Et Al. }, title={Bleeding risk with concomitant use of tirofiban and third-generation P2Y12 receptor antagonists in patients with acute myocardial infarction: A real-life data.}, journal={Anatolian journal of cardiology}, year=2021, pages={699-705} }